{
  "url": "https://en.wikipedia.org/wiki/Boehringer_Ingelheim",
  "title": "Boehringer Ingelheim",
  "header": [
    [
      "Drug Name",
      []
    ],
    [
      "Description",
      []
    ],
    [
      "Potential Indication",
      []
    ],
    [
      "Testing Phase",
      []
    ]
  ],
  "data": [
    [
      [
        "Olodaterol",
        [
          "/wiki/Olodaterol"
        ]
      ],
      [
        "Long-acting beta-agonist",
        [
          "/wiki/Long-acting_beta-agonist"
        ]
      ],
      [
        "Chronic obstructive pulmonary disease ( COPD )",
        [
          "/wiki/Chronic_obstructive_pulmonary_disease"
        ]
      ],
      [
        "Approved",
        []
      ]
    ],
    [
      [
        "Tiotropium",
        [
          "/wiki/Tiotropium"
        ]
      ],
      [
        "Long acting muscarinic antagonist",
        []
      ],
      [
        "Cystic fibrosis ( CF ) / asthma . Already approved for chronic obstructive pulmonary disease ( COPD )",
        [
          "/wiki/Cystic_fibrosis",
          "/wiki/Asthma",
          "/wiki/Chronic_obstructive_pulmonary_disease"
        ]
      ],
      [
        "Approved",
        []
      ]
    ],
    [
      [
        "Nintedanib",
        [
          "/wiki/Nintedanib"
        ]
      ],
      [
        "Triple angiokinase inhibitor , simultaneously blocks VEGFR , FGFR , PDGFR",
        [
          "/wiki/VEGFR",
          "/wiki/FGFR",
          "/wiki/PDGFR"
        ]
      ],
      [
        "Idiopathic pulmonary fibrosis ( IPF ) / non-small cell lung cancer ( NSCLC ) / ovarian cancer",
        [
          "/wiki/Idiopathic_pulmonary_fibrosis",
          "/wiki/Non-small_cell_lung_cancer",
          "/wiki/Ovarian_cancer"
        ]
      ],
      [
        "Phase III",
        []
      ]
    ],
    [
      [
        "Afatinib",
        [
          "/wiki/Afatinib"
        ]
      ],
      [
        "Irreversible ErbB family blocker",
        [
          "/wiki/ErbB"
        ]
      ],
      [
        "Breast cancer / head and neck cancer . Already approved for non-small cell lung cancer ( NSCLC )",
        [
          "/wiki/Breast_cancer",
          "/wiki/Head_and_neck_cancer",
          "/wiki/Non-small_cell_lung_cancer"
        ]
      ],
      [
        "Phase III",
        []
      ]
    ],
    [
      [
        "Volasertib",
        [
          "/wiki/Volasertib"
        ]
      ],
      [
        "PLK1 antagonist",
        [
          "/wiki/PLK1"
        ]
      ],
      [
        "Various cancer types",
        []
      ],
      [
        "Phase III",
        []
      ]
    ],
    [
      [
        "Deleobuvir ( formerly BI 207127 )",
        [
          "/wiki/Deleobuvir"
        ]
      ],
      [
        "NS5B RNA-dependent polymerase inhibitor",
        [
          "/wiki/NS5B"
        ]
      ],
      [
        "Hepatitis C",
        [
          "/wiki/Hepatitis_C"
        ]
      ],
      [
        "Phase III",
        []
      ]
    ],
    [
      [
        "Faldaprevir ( formerly BI 201335 )",
        [
          "/wiki/Faldaprevir"
        ]
      ],
      [
        "NS3 / 4A protease inhibitor",
        [
          "/wiki/NS3_(HCV)",
          "/wiki/NS4A"
        ]
      ],
      [
        "Hepatitis C",
        [
          "/wiki/Hepatitis_C"
        ]
      ],
      [
        "Phase III",
        []
      ]
    ],
    [
      [
        "Empagliflozin",
        [
          "/wiki/Empagliflozin"
        ]
      ],
      [
        "SGLT-2 -inhibitor",
        [
          "/wiki/SGLT-2"
        ]
      ],
      [
        "Diabetes mellitus type II",
        [
          "/wiki/Diabetes_mellitus_type_II"
        ]
      ],
      [
        "Approved",
        []
      ]
    ],
    [
      [
        "Idarucizumab",
        [
          "/wiki/Idarucizumab"
        ]
      ],
      [
        "Humanized antibody fragment ( FAB ) , specific reversal agent to dabigatran",
        [
          "/wiki/Dabigatran"
        ]
      ],
      [
        "Reversal of dabigatran-induced anticoagulation in case of an emergency",
        [
          "/wiki/Anticoagulation"
        ]
      ],
      [
        "Phase III",
        []
      ]
    ]
  ],
  "section_title": "Products -- Product pipeline",
  "section_text": "Boehringer Ingelheim 's product pipeline targets lung disease , cancer , and hepatitis C. [ 40 ]",
  "uid": "Boehringer_Ingelheim_0",
  "intro": "C.H. Boehringer Sohn AG & Ko. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one. Headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. Unlike most large pharmaceutical companies which are listed, the company is private and fully owned by the Boehringer, Liebrecht and von Baumbach families. The company's key areas of interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne."
}